Evidence map›Paper›PMID 33550140›Full record

ReviewStem cell research2021

Structural insights into SARS-CoV-2 infection and therapeutics development.

Gangyu Sun, Lulu Xue, Qingjing He, Yue Zhao, Wenqing Xu, Zhizhi Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. SARS-CoV-2 PLChemistryOpen · 2024
    Article
  3. Wuhan Sequence-Based Recombinant Antigens Expressed inInternational journal of molecular sciences · 2024
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gangyu SunSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Lulu XueSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Qingjing HeSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Yue ZhaoSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Wenqing XuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Zhizhi WangSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China. Electronic address: wangzhzh@shanghaitech.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current COVID-19 pandemic is caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). By late October 2020, more than 43 million cases of infections, including over 1.15 million deaths, have been confirmed worldwide. This review focuses on our current understanding of SARS-CoV-2 from the perspective of the three-dimensional (3D) structures of SARS-CoV-2 viral proteins and their implications on therapeutics development against COVID-19.

Indexed as

COVID-19 Drug TreatmentAntibodies, ViralCOVID-19Genome, ViralHumansIon ChannelsProtein ConformationSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralIon ChannelsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Main proteaseNspRdRpSARS-CoV-2Spike proteinStructure

Identifiers

PMID33550140
PMCPMC7985237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.